Dr. Sanjay Gupta

The landscape has changed a lot since we first reported on these drugs on Chasing Life.

So today we're bringing back my friend and colleague Meg Terrell, who has been covering them since the start.

She's going to update us on what is new, what's on the horizon.

And let me tell you, there's a lot to talk about.

I'm CNN Chief Medical Correspondent Dr. Sanjay Gupta, and this is Chasing Life.

Welcome back to Chasing Life.

Thank you for having me.

My favorite guest.

You and I, we know each other so well.

We work together, but I just so respect your reporting.

And I don't know if you realize this, but the last time we talked about GLP drugs was more than two years ago.

We talk about it all the time, yes.

We have a lot of conversations, Meg and I. But yeah, for the podcast, for our audience two years ago, and there's a lot that has changed since then, and I want to really focus on that.

But I'm just curious, overall, just the headline here.

I think it was 2017 or so when Ozempic hit the market.

How big a deal really are these GLP drugs now in the market?

Yeah.

You're talking about in terms of money spent on them?

Does this surprise you?

And I'll preface by saying you've been covering this for a long time, I think since the start, you know, here obviously, but also at CNBC.